Shirai T, Lee M S, Wang C Y, King C M
Cancer Res. 1981 Jun;41(6):2450-6.
The objective of this study was to investigate the induction of liver tumors by arylhydroxamic acids. The potential involvement of sulfate conjugation was minimized by the administration of a N-hydroxy-4-acylaminobiphenyl to female CD rats. This experimental design provided for the exposure of a target organ that has only a low capacity for activation of hydroxamic acids by sulfate conjugation, with a carcinogen that does not induce tumors in liver that possess a high sulfotransferase activity. A single dose of the N-formyl or N-acetyl derivatives of N-hydroxy-4-aminobiphenyl was given i.p. at 0.4 mmol/kg body weight to 34-day-old animals. In attempts to amplify the hepatocarcinogenic potential of the compounds, partial hepatectomy 24 hr before the chemical injection and subsequent long-term treatment with phenobarbital in the diet were carried out. For comparative purposes, other animals were subjected to three additional partial hepatectomies subsequent to the carcinogen administration instead of the phenobarbital treatment. The experiments were terminated 64 weeks after injection. Both the N-formyl and N-acetyl derivatives of N-hydroxy-4-aminobiphenyl, in conjunction with partial hepatectomy and subsequent treatment of dietary phenobarbital, induced a high incidence of neoplastic nodules and gamma-glutamyltranspeptidase-positive foci in the liver. Only one hepatocellular carcinoma was observed in each treatment group. Repeated partial hepatectomies enhanced the yield of gamma-glutamyltranspeptidase-positive foci but were ineffective in producing neoplastic nodules. In addition to the liver lesions, mammary tumors were also induced. Importantly, an inhibitory effect of the subsequent administration of phenobarbital was observed on mammary tumor formation, possibly because of alterations in hormone metabolism resulting from the induction of microsomal enzymes by phenobarbital, which resulted in a decreased promoting effect. There was no difference in the tumorigenicity of the formyl and acetyl derivatives in these experiments.
本研究的目的是调查芳基异羟肟酸对肝脏肿瘤的诱导作用。通过给雌性CD大鼠施用N-羟基-4-酰氨基联苯,使硫酸结合的潜在参与降至最低。这种实验设计使得仅具有低硫酸结合能力来激活异羟肟酸的靶器官暴露于一种在具有高磺基转移酶活性的肝脏中不诱导肿瘤的致癌物。将N-羟基-4-氨基联苯的N-甲酰基或N-乙酰基衍生物以0.4 mmol/kg体重腹腔注射给34日龄的动物。为了增强这些化合物的肝癌致癌潜力,在化学注射前24小时进行部分肝切除术,并随后在饮食中用苯巴比妥进行长期治疗。为了进行比较,其他动物在给予致癌物后进行另外三次部分肝切除术,而不是进行苯巴比妥治疗。注射后64周终止实验。N-羟基-4-氨基联苯的N-甲酰基和N-乙酰基衍生物,与部分肝切除术及随后的饮食苯巴比妥治疗相结合,在肝脏中诱导出高发生率的肿瘤结节和γ-谷氨酰转肽酶阳性灶。每个治疗组仅观察到一例肝细胞癌。重复进行部分肝切除术提高了γ-谷氨酰转肽酶阳性灶的发生率,但对产生肿瘤结节无效。除肝脏病变外,还诱导出了乳腺肿瘤。重要的是,观察到随后给予苯巴比妥对乳腺肿瘤形成有抑制作用,这可能是由于苯巴比妥诱导微粒体酶导致激素代谢改变,从而降低了促进作用。在这些实验中,甲酰基和乙酰基衍生物的致瘤性没有差异。